Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 17 07 2020
revised: 08 08 2020
accepted: 11 08 2020
entrez: 29 9 2020
pubmed: 30 9 2020
medline: 8 10 2020
Statut: ppublish

Résumé

Despite improved treatment for gastric cancer (GC), the prognosis of advanced disease remains poor. Further investigation of the oncogenic sequence for GC is needed. The expression of TYRO3 protein tyrosine kinase in five GC cell lines was confirmed using western blotting. TYRO3 knockdown in GC cells, and bromodeoxyuridine and Transwell assays were used to examine the functions of TYRO3 in tumor proliferation and invasion. Finally, TYRO3 expression in 138 patients who underwent curative gastric resection for advanced GC (Union for International Cancer Control stage II/III) was tested by immunohistochemistry, and the association between prognosis and TYRO3 expression was analyzed. TYRO3 was detected at various levels in all the tested GC cell lines. Deleting TYRO3 significantly suppressed proliferation and invasion. Immunohistochemistry revealed TYRO3 expression was an independent prognostic factor for overall survival in patients with GC. TYRO3 appears to mediate tumor progression and predict prognosis of patients with GC.

Sections du résumé

BACKGROUND BACKGROUND
Despite improved treatment for gastric cancer (GC), the prognosis of advanced disease remains poor. Further investigation of the oncogenic sequence for GC is needed.
MATERIALS AND METHODS METHODS
The expression of TYRO3 protein tyrosine kinase in five GC cell lines was confirmed using western blotting. TYRO3 knockdown in GC cells, and bromodeoxyuridine and Transwell assays were used to examine the functions of TYRO3 in tumor proliferation and invasion. Finally, TYRO3 expression in 138 patients who underwent curative gastric resection for advanced GC (Union for International Cancer Control stage II/III) was tested by immunohistochemistry, and the association between prognosis and TYRO3 expression was analyzed.
RESULTS RESULTS
TYRO3 was detected at various levels in all the tested GC cell lines. Deleting TYRO3 significantly suppressed proliferation and invasion. Immunohistochemistry revealed TYRO3 expression was an independent prognostic factor for overall survival in patients with GC.
CONCLUSION CONCLUSIONS
TYRO3 appears to mediate tumor progression and predict prognosis of patients with GC.

Identifiants

pubmed: 32988883
pii: 40/10/5593
doi: 10.21873/anticanres.14572
doi:

Substances chimiques

Biomarkers, Tumor 0
Receptor Protein-Tyrosine Kinases EC 2.7.10.1
TYRO3 protein, human EC 2.7.10.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5593-5600

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Chihiro Uejima (C)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Masaki Morimoto (M)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan 2s.morimoto@gmail.com.

Manabu Yamamoto (M)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Kazushi Hara (K)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Wataru Miyauchi (W)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Ken Sugezawa (K)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Yoichiro Tada (Y)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Akimitsu Tanio (A)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Kyoichi Kihara (K)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Tomoyuki Matsunaga (T)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Naruo Tokuyasu (N)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Teruhisa Sakamoto (T)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Soichiro Honjo (S)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Yoshihisa Umekita (Y)

Department of Pathology, Division of Organ Pathology, Faculty of Medicine, Tottori University, Yonago, Japan.

Yoshiyuki Fujiwara (Y)

Department of Surgery, Division of Gastrointestinal and Pediatric Surgery, Faculty of Medicine, Tottori University, Yonago, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH